Citadel Advisors’s Addex Therapeutics ADXN Stock Holding History

Citadel Advisors’s Portfolio ADXN Stock Details ADXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,741	Closed	-$86.2K	–	12345
2025 Q1	$86.2K	Sell	11,741 -338	-3%	-$2.62K	﹤0.01%	11677
2024 Q4	$84.6K	Buy	+12,079	New	+$110K	﹤0.01%	11709
2023 Q2	–	Sell	-1,719	Closed	-$32.5K	–	14262
2023 Q1	$32.5K	Sell	1,719 -350	-17%	-$8.84K	﹤0.01%	12650
2022 Q4	$26.1K	Buy	2,069 +1,429	+223%	+$21.1K	﹤0.01%	12899
2022 Q3	$10K	Buy	+640	New	+$14.3K	﹤0.01%	12271
2021 Q2	–	Sell	-580	Closed	-$121K	–	13579
2021 Q1	$121K	Buy	+580	New	+$130K	﹤0.01%	12283

Other funds holding ADXN

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citadel Advisors's ADXN Position: Q2 2025 in Review

Citadel Advisors sold out of Addex Therapeutics (ADXN) in Q2 2025, closing a stake of 11,741 shares — an estimated $86.2K sold.

Citadel Advisors first reported a position in ADXN in Q1 2021 and held it in 6 quarters. The position peaked at $121K in Q1 2021. 5 funds tracked by Wall St. Rank hold ADXN as of Q2 2025.

Citadel Advisors reported no remaining Addex Therapeutics position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 11,741 Addex Therapeutics shares in Q2 2025, an estimated $86.2K.
Citadel Advisors first reported a position in Addex Therapeutics in Q1 2021 and held it in 6 quarters.
Citadel Advisors's Addex Therapeutics position peaked at $121K in Q1 2021.
5 funds tracked by Wall St. Rank held Addex Therapeutics as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.